Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIC: Teprotumumab in Active Thyroid Eye Disease
NCT03298867Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2017
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of teprotumumab in thyroid eye disease (TED), sponsored by Amgen. Primary endpoint: Percentage of Participants Who Were Proptosis Responders at 24 weeks. Started Oct 2017; status: completed.
02
Drugs
teprotumumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT03298867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298867.